THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [8.35] ID: TIP-MED-000163

Oseltamivir Phosphate

Active Ingredient / Scientific Identity: Oseltamivir Phosphate • Class: Influenza A & B Viral Neuraminidase Inhibitor (Schedule H1 | NLEM 2022)

⚖️ Compare Profile
Generic / Entity NameOseltamivir Phosphate ([8.35])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassInfluenza A & B Viral Neuraminidase Inhibitor (Schedule H1 | NLEM 2022)
Available Dosage FormsCapsules: 30 mg, 45 mg, 75 mg; Oral Suspension Powder: 12 mg/mL
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal (CrCl — active carboxylate is >90% renally excreted!): CrCl >60 mL/min: 75 mg BD; CrCl 31–60 mL/min: Reduce Treatment t
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Oseltamivir Phosphate (TIP-MED-000163, Reference Code [8.35]) is classified under Antimicrobials — Antiviral & Antiretroviral Agents (Ch 08) as a Influenza A & B Viral Neuraminidase Inhibitor (Schedule H1 | NLEM 2022). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.35], p. 110): Fluvir (Hetero), Antiflu (Cipla), Tamiflu (Roche), Natflu (Natco) — Strengths & Dosage Forms: Capsules: 30 mg, 45 mg, 75 mg; Oral Suspension Powder: 12 mg/mL
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.35], p. 110): Fluvir (Hetero), Antiflu (Cipla), Tamiflu (Roche), Natflu (Natco) — Strengths & Dosage Forms: Capsules: 30 mg, 45 mg, 75 mg; Oral Suspension Powder: 12 mg/mL
Dosage Forms & Available Strengths:
Capsules: 30 mg, 45 mg, 75 mg; Oral Suspension Powder: 12 mg/mL
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Influenza A & B Viral Neuraminidase Inhibitor (Schedule H1 | NLEM 2022) acting on target receptor/enzyme pathways in Antimicrobials — Antiviral & Antiretroviral Agents (Ch 08): clinical efficacy is mediated via Influenza A & B Viral Neuraminidase Inhibitor (Schedule H1 | NLEM 2022) for Treatment and post-exposure prophylaxis of Influenza A (including H1N1 / H3N2 strains) and Influenza B in high-risk outpatients (age >=65 yr, pregnancy, asthma/COPD, diabetes, heart/renal disease) and all hospitalised influenza patients.

4. Therapeutic Indications & Evidence-Supported Uses

  • Treatment and post-exposure prophylaxis of Influenza A (including H1N1 / H3N2 strains) and Influenza B in high-risk outpatients (age >=65 yr, pregnancy, asthma/COPD, diabetes, heart/renal disease) and all hospitalised influenza patients

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Treatment (Adults & >=40 kg): 75 mg PO TWICE DAILY (q12h) for 5 DAYS. Paediatric Weight-Based Treatment (BD x 5d): <=15 kg: 30 mg BD; >15–23 kg: 45 mg BD; >23–40 kg: 60 mg BD; >40 kg: 75 mg BD. Prophylaxis: 75 mg PO ONCE DAILY for 10 days

Administration & Meal Timing: Initiate as early as possible (ideally within 48 hours of symptom onset, though hospitalised/pregnant/severe H1N1 patients benefit even when started >48h after onset!). Take WITH food or milk to reduce nausea! | Morning & Evening (12-hourly BD for Treatment; Once Daily for Prophylaxis)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal (CrCl — active carboxylate is >90% renally excreted!): CrCl >60 mL/min: 75 mg BD; CrCl 31–60 mL/min: Reduce Treatment to 30 mg BD (Prophylaxis: 30 mg OD); CrCl 11–30 mL/min: Reduce Treatment to 30 mg ONCE DAILY; Haemodialysis: 30 mg after each HD session!
Elimination & Renal Adjustment:
Renal (CrCl — active carboxylate is >90% renally excreted!): CrCl >60 mL/min: 75 mg BD; CrCl 31–60 mL/min: Reduce Treatment to 30 mg BD (Prophylaxis: 30 mg OD); CrCl 11–30 mL/min: Reduce Treatment to 30 mg ONCE DAILY; Haemodialysis: 30 mg after each HD session!
Hepatic Impairment Considerations:
Renal (CrCl — active carboxylate is >90% renally excreted!): CrCl >60 mL/min: 75 mg BD; CrCl 31–60 mL/min: Reduce Treatment to 30 mg BD (Prophylaxis: 30 mg OD); CrCl 11–30 mL/min: Reduce Treatment to 30 mg ONCE DAILY; Haemodialysis: 30 mg after each HD session!

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • REGULATORY UPDATE: Moved by MoHFW notification G.S.R. 292(E) from Schedule X to Schedule H1 (requires valid RMP prescription and 3-year Schedule H1 register entry!). Safe and strongly recommended across ALL trimesters of pregnancy!

Key Clinical Precautions: Renal (CrCl — active carboxylate is >90% renally excreted!): CrCl >60 mL/min: 75 mg BD; CrCl 31–60 mL/min: Reduce Treatment to 30 mg BD (Prophylaxis: 30 mg OD); CrCl 11–30 mL/min: Reduce Treatment to 30 mg ONCE DAILY; Haemodialysis: 30 mg after each HD session!

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Nausea and vomiting (10–15% — markedly reduced by taking with food), headache, abdominal pain
  • Rare neuropsychiatric events (delirium, hallucinations, abnormal behaviour — primarily in children/adolescents with influenza!), SJS/TEN, anaphylaxis
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Avoid Live Attenuated Influenza Vaccine (LAIV nasal spray) within 2 weeks before or 48 hours after Oseltamivir (Inactivated Injectable Flu Vaccine can be given at any time!)
  • Minimal CYP450 interactions

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Start within 48 hours of flu fever/cough; take with food to prevent nausea; safe and life-saving during pregnancy; adjust to 30 mg capsule in kidney disease; seek emergency care if breathlessness or SpO2 <94% develops
  • Meal & Clock Timing Instruction: Initiate as early as possible (ideally within 48 hours of symptom onset, though hospitalised/pregnant/severe H1N1 patients benefit even when started >48h after onset!). Take WITH food or milk to reduce nausea! (Morning & Evening (12-hourly BD for Treatment; Once Daily for Prophylaxis))
  • Missed Dose Protocol: Take as soon as remembered unless within 2 hours of next dose; complete the full 5-day course
  • Geriatric Dispensing Pearl: Always check CrCl in older adults — if CrCl is 31–60 mL/min, dispense the 30 mg capsule BD (not 75 mg BD!)

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Capsules: 30 mg, 45 mg, 75 mg; Oral Suspension Powder: 12 mg/mL

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.35] (p. 110)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.